- Renalytix AI plc (NASDAQ: RNLX) stock is rising on the heels of a 10-year contract from the United States Government to provide KidneyIntelX early-stage kidney disease bioprognostic testing services.
- The contract, offered through the General Services Administration, covers laboratory testing services that can be provided through more than 140 U.S. government departments, agencies.
- The contract is effective as of April 15 and has a five-year term with a five-year extension option.
- Under the contract, KidneyIntelX pricing is set at $950 per reportable result.
- Individual physicians operating within government-sponsored healthcare programs can now order KidneyIntelX testing for their patients with diabetic kidney disease.
- Price Action: RNLX shares are up 21.7% at $30.7 in the premarket session on the last check Thursday.
Core Molding Technologies Q2 EPS $0.48 Up From $(0.29) YoY, Sales $80.50M Up From $37.81M YoY
Core Molding Technologies (AMEX:CMT) reported quarterly earnings of $0.48 per share. This is a 265.52 percent increase over losses of $(0.29) per share from the same period last year. The company reported $80.50 million
